Launch of Generic Semaglutide in India
Following the expiration of Novo Nordisk’s patent on semaglutide, various generic versions of the drug are set to hit the Indian market starting March 21, 2026. Several major pharmaceutical companies are expected to release a total of approximately 50 different brands, making this popular weight loss medication more accessible to the public.
The anticipated cost reduction of semaglutide will be between 20% to 33%, providing a significant relief for those who struggle with weight loss. Health experts note that while semaglutide can significantly aid in weight management, it should be combined with lifestyle changes, including proper diet and exercise.
Background on Semaglutide
Initially developed for treating Type 2 diabetes, semaglutide has gained popularity as a weight loss drug under the brand names Ozempic and Wegovy. In India, recent statistics indicate an alarming upward trend in obesity rates, which affect an estimated 254 million people. The rise in obesity-related health issues underscores the importance of accessible treatments.
According to studies, the prevalence of obesity in Indian males rose from 15.3 million in 1990 to over 81 million by 2021. Predictive models project an increase to roughly 218 million by 2050. Similarly, obesity in Indian women has followed a similar trajectory, rising from 21.4 million in 1990 to nearly 98 million in 2021, with projections indicating nearly 231 million women may be affected by mid-century.
Details of Generic Brands Entering the Market
Notable Launches
Companies like Natco Pharmaceuticals have announced plans to sell their generic brands, such as ‘Semanat’ and ‘Semafull’ in varying dosages (2mg, 4mg, and 8mg). For the lowest dosage, the monthly cost is set at ₹1,290, while the highest dose will be priced at ₹1,750. Furthermore, the company plans to introduce an easy-to-inject pen device next month, priced between ₹4,000 and ₹4,500 based on the dosage.
Zydus will market three distinct brands: ‘Semaglyn’, ‘Mashema’, and ‘Alterme’. Additionally, they have partnered with Lupin and Torrent to market semaglutide pens under the names Semanext, Livarise, and Sembolic. Sun Pharma’s offerings, branded as Noveltreat, will provide five different dosages ranging from 0.25 mg to 2.4 mg.
Price Comparison with Original Brands
The pricing of the generic versions stands in stark contrast to the original products. For instance, Novo Nordisk’s Ozempic is priced between ₹8,800 and ₹11,175 monthly, while Wegovy can cost between ₹10,850 and ₹16,400. This difference means that those seeking weight loss options might find generics a more viable choice.
Prescription Requirement and Usage
It is crucial to note that these medications will only be available with a prescription from registered medical practitioners. Doctors emphasize the importance of continuing lifestyle interventions even after starting semaglutide to achieve the best results in weight management. The lower-dose versions are primarily for managing Type 2 diabetes, while higher doses are designated for individuals classified as obese or overweight with associated health complications.
Rising Obesity Crisis in India
The staggering rise in obesity rates in India reinforces the necessity for effective treatment options. Abdominal obesity alone, which heightens the risk of serious health conditions, affects over 351 million people when considering body fat distribution. The worsening statistics signify a healthcare challenge that demands immediate attention and long-term strategies.
Children are not excluded from this increasing trend; research indicates that overweight and obese boys have risen from 4.6 million in 1990 to 13.3 million in 2021, with projections indicating 16 million by 2050. For girls, these figures show a rise from 4.5 million to 12.4 million, expected to increase to 14.4 million by 2050. These concerning trends across all age demographics highlight the urgency of implementing comprehensive healthcare policies.
World Health Organization Guidelines and Chronic Disease Perspective
The World Health Organization has redefined obesity as a chronic, lifelong disease requiring holistic treatment approaches encompassing therapies and lifestyle changes. Recent recommendations advocate for long-term, multi-faceted options for managing obesity, including combining pharmacological options like semaglutide with surgical interventions and sustained lifestyle changes.
According to the recent Lancet Commission, obesity must be viewed not merely through the lens of BMI but as a complex medical condition affecting organ function and overall health. The distinction between ‘preclinical’ and ‘clinical’ obesity is also important, as the former might indicate a risk factor but not necessarily qualify as an illness, while the latter is associated with significant health complications.
Future Implications and Conclusion
The availability of generic semaglutide can lead to transformative changes in obesity management in India. Experts hope this will motivate healthcare systems to take a proactive stance in obesity treatment by ensuring the availability and affordability of these medications. The crux of managing obesity goes beyond merely prescribing medication; it requires ongoing support, consistent monitoring, and lifestyle interventions.
Authorities have not yet specified the exact launch date for every generic brand, but they expect the products to be available in local pharmacies shortly. Patient education will also be crucial in guiding individuals on how to integrate the use of semaglutide effectively within their overall treatment plans.
As these new treatments become widely available, continued collaboration between healthcare providers and pharmaceutical companies will be essential in addressing India’s obesity crisis head-on, promoting healthier lifestyles for millions.